 |
|
|
| |
High Rates of SVR24 for BMS-790052, an NS5A
Replication Complex Inhibitor, in Combination With
PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in
Treatment-Naive HCV Genotype 1 Subjects
|
| |
| |
Reported by Jules Levin
51st ICAAC, Chicago
September 17-20, 2011
Oral Abstract H1-376
Pol S,1 Ghalib RH,2 Rustgi VK,3 Martorell C,4 Everson GT,5 Tatum HA,6 Hezode C,7 Lim JK,8 Bronowicki J-P,9 Abrams GA,10 Brau N,11 Morris DW,12 Thuluvath PJ,13 Reindollar RW,14 Yin PD,15 Diva U,15 Hindes R,15 McPhee F,15 Gao M,15 Hughes EA,16 Schnittman S15
1Hopital Cochin, Paris, France; 2The Liver Institute at Methodist Dallas Medical Center, TX; 3Metropolitan Research, Fairfax, VA; 4The Research Institute, Springfield, MA; 5University of Colorado Denver and University of Colorado Hospital, Aurora, CO; 6Options Health Research, Tulsa, OK; 7CHU Henri Mondor, Creteil, France; 8Yale University School of Medicine, New Haven, CT; 9Hopital d'Adultes de Brabois, Vandoeuvre-les-Nancy, France; 10Alabama Liver and Digestive Specialists, Montgomery, AL; 11James J Peters VAMC, Bronx, NY; 12Healthcare Research Consultants, Tulsa, OK; 13Mercy Medical Center, Baltimore, MD; 14Carolinas Center for Liver Disease Research, Statesville, NC; 15Bristol-Myers Squibb Research and Development, Wallingford, CT; 16Bristol-Myers Squibb Research and Development, Princeton, NJ
|
| |
|
|
|
|
|
